EP4692096A1 — Macrocyclic compound, and pharmaceutical composition and use thereof
Assigned to Prime Gene Therapeutics Co Ltd · Expires 2026-02-11 · 0y expired
What this patent protects
The present disclosure relates to a macrocyclic compound, a pharmaceutical composition and use thereof. The compound has a structural formula as shown in Formula I. The macrocyclic compound is a highly selective TYK2 allosteric inhibitor with strong blood-brain barrier penetratio…
USPTO Abstract
The present disclosure relates to a macrocyclic compound, a pharmaceutical composition and use thereof. The compound has a structural formula as shown in Formula I. The macrocyclic compound is a highly selective TYK2 allosteric inhibitor with strong blood-brain barrier penetration that can be used to regulate TYK2-mediated diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.